JPH06247871A - Growth promoter - Google Patents
Growth promoterInfo
- Publication number
- JPH06247871A JPH06247871A JP5057960A JP5796093A JPH06247871A JP H06247871 A JPH06247871 A JP H06247871A JP 5057960 A JP5057960 A JP 5057960A JP 5796093 A JP5796093 A JP 5796093A JP H06247871 A JPH06247871 A JP H06247871A
- Authority
- JP
- Japan
- Prior art keywords
- angiogenin
- growth promoter
- growth
- active ingredient
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007952 growth promoter Substances 0.000 title claims abstract description 13
- 108010072788 angiogenin Proteins 0.000 claims abstract description 56
- 102100022987 Angiogenin Human genes 0.000 claims abstract description 54
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 239000007857 degradation product Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 108090001109 Thermolysin Proteins 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 101000757236 Homo sapiens Angiogenin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710190946 Angiogenin-3 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- DFIWJEVKLWMZBI-UHFFFAOYSA-M sodium;dihydrogen phosphate;phosphoric acid Chemical compound [Na+].OP(O)(O)=O.OP(O)([O-])=O DFIWJEVKLWMZBI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、アンジオジェニンおよ
び/ またはその分解物を有効成分とする発育促進剤に関
する。この発育促進剤は、特に乳幼児あるいは幼若動物
の発育を促進するために有用である。TECHNICAL FIELD The present invention relates to a growth promoter containing angiogenin and / or its degradation product as an active ingredient. This growth promoter is particularly useful for promoting the growth of infants and young animals.
【0002】[0002]
【従来の技術】アンジオジェニンは、血管形成誘導作用
を示す分子量が約14kDaの蛋白質で、ヒト腸の癌細
胞培養液から初めて単離され〔Biochem.、第2
4巻、5480〜5486頁、1985年〕、その後、
ヒト正常細胞からも単離されることが知られている〔B
iochem.、第26巻、5141〜5146頁、1
987年〕。そして、ヒトアンジオジェニンは、他の血
管形成誘導作用を示す蛋白質である acidic a
nd basic fibroblast growt
h factor(FGF)、transformin
g growthfactor α(TGF−α)、t
ransforming growthfactor
β(TGF−β)、tumor necrosis f
actor γ(TNF−γ)などと同様、ピコモルの
オーダーで血管形成誘導作用を示すことがFettらに
よって報告されている〔Biochem.、第24巻、
5480〜5486頁、1985年〕。また、ウシアン
ジオジェニンもヒトアンジオジェニンと同等の活性を示
すことがMichaelらによって報告されている〔B
iochem.、第27巻、6282〜6287頁、1
988年〕。したがって、アンジオジェニンは、血管新
生因子としての性質を利用した用途、特に外傷、潰瘍、
循環機能、移殖などの治療剤として、その利用が期待さ
れる物質である。また、アンジオジェニンを有効成分と
する養毛剤についても提案されている〔特開平4−21
0618号公報〕。BACKGROUND OF THE INVENTION Angiogenin is a protein having an angiogenesis-inducing action and having a molecular weight of about 14 kDa, and was first isolated from a human intestine cancer cell culture medium [Biochem. , Second
4, 5480-5486, 1985], and then
It is also known to be isolated from normal human cells [B
iochem. 26, 5141-5146, 1
987]. And, human angiogenin is another protein that shows angiogenic action, acidica
nd basic fibroblast growt
h factor (FGF), transformin
g growth factor α (TGF-α), t
transforming growfactor
β (TGF-β), tumor necrosis f
It has been reported by Fett et al. that it exhibits an angiogenesis-inducing action on the order of picomoles as in the case of actor γ (TNF-γ) and the like [Biochem. , Volume 24,
5480-5486, 1985]. In addition, it was reported by Michael et al. That bovine diogenin exhibits an activity equivalent to that of human angiogenin [B
iochem. , Vol. 27, pp. 6282-6287, 1
988]. Therefore, angiogenin is used for its use as an angiogenic factor, especially for trauma, ulcers,
It is a substance expected to be used as a therapeutic agent for circulatory function and transplantation. A hair nourishing agent containing angiogenin as an active ingredient has also been proposed [JP-A-4-21].
No. 0618].
【0003】一方、アンジオジェニンの調製法として
は、ヒト腺癌細胞系であるHT−29の培養液を酸沈澱
し、濾過した後、陽イオン交換体(CM52、ワットマ
ン社製) で処理し、逆相クロマトグラフィーにより精製
するFettらの方法〔Biochem.、第24巻、
5480〜5486頁、1985年〕、ヒト血漿を陽イ
オン交換体で処理し、再度、陽イオン交換体で処理した
後、逆相クロマトグラフィーにより精製するShapi
roらの方法〔Biochem.、第26巻、5141
〜5146頁、1987年〕が知られている。また、B
ondらは、Shapiroらの方法と同様な方法で、
ウシ血清からアンジオジェニンを大量に調製したことを
報告している〔Biochem.、第27巻、6282
〜6287頁、1988年〕。さらに、Spikらは、
牛乳を陽イオン交換体(SP−セファデックス C−5
0、ファルマシア社製) で処理し、再度、陽イオン交換
体(S−セファロース ファースト フロー、ファルマ
シア社製) で処理するアンジオジェニンの製造法を提案
している〔特開平2−269000号公報〕。On the other hand, as a method for preparing angiogenin, a culture solution of human adenocarcinoma cell line HT-29 is acid-precipitated, filtered, and then treated with a cation exchanger (CM52, Whatman). The method of Fett et al. [Biochem. , Volume 24,
5480-5486, 1985], human plasma is treated with a cation exchanger, treated again with a cation exchanger, and then purified by reverse phase chromatography.
Ro et al. [Biochem. , Volume 26, 5141
Pp. 5146, 1987] is known. Also, B
ond et al., in a manner similar to the method of Shapiro et al.
It has been reported that a large amount of angiogenin was prepared from bovine serum [Biochem. , Vol. 27, 6282
~ 6287, 1988]. Furthermore, Spik et al.
Milk is a cation exchanger (SP-Sephadex C-5
No. 0, manufactured by Pharmacia), and again treated with a cation exchanger (S-Sepharose Fast Flow, manufactured by Pharmacia), and a method for producing angiogenin is proposed [JP-A-2-269000].
【0004】[0004]
【発明が解決しようとする課題】本発明者らは、乳中に
特に多量に含まれるアンジオジェニンの新たな用途につ
いて検討する過程で、アンジオジェニンが乳幼児あるい
は幼若動物に何らかの生理作用を示すのではないかと考
え、ラットを用いてアンジオジェニン投与試験を行った
ところ、アンジオジェニンを投与することで幼若ラット
の発育が促進されることを見出した。また、アンジオジ
ェニンの分解物についても同様の試験を行ったところ、
アンジオジェニンと同様の効果を示すことを見出し、ラ
ットの発育が促進されることが明らかになり本発明を完
成するに至った。したがって、本発明は、アンジオジェ
ニンおよび/またはその分解物を有効成分とする発育促
進剤を提供することを課題とする。DISCLOSURE OF THE INVENTION In the process of examining new uses of angiogenin, which is contained in milk in a particularly large amount, the present inventors show that angiogenin has some physiological action on infants and young animals. We suspected that this might be the case, and conducted an angiogenin administration test in rats, and found that the administration of angiogenin promoted the growth of young rats. In addition, when a similar test was performed on a decomposed product of angiogenin,
It was found that the same effect as that of angiogenin was exhibited, and it was revealed that the growth of rats was promoted, and the present invention was completed. Therefore, it is an object of the present invention to provide a growth promoter containing angiogenin and / or its degradation product as an active ingredient.
【0005】[0005]
【課題を解決するための手段】本発明で発育促進剤の有
効成分として用いるアンジオジェニンの入手方法につい
ては特に限定されるものではなく、ヒト、ウシ、ブタな
どの哺乳動物の乳や血液から調製したもの、あるいは遺
伝子組み換え技術によって製造したものなどを用いるこ
とができる。なお、本発明の発育促進剤を飲食品、化粧
品あるいは飼料に配合して用いる場合、特に高度に精製
されたアンジオジェニンを使用する必要はなく、例えば
ラクトフェリンなどを含有していても問題はない。The method of obtaining angiogenin used as an active ingredient of a growth promoting agent in the present invention is not particularly limited, and it is prepared from milk or blood of mammals such as humans, cows and pigs. Those produced, or those produced by gene recombination technology can be used. When the growth promoting agent of the present invention is used in foods, drinks, cosmetics or feeds, it is not necessary to use highly purified angiogenin, and there is no problem even if it contains lactoferrin.
【0006】本発明で発育促進剤の有効成分として用い
るアンジオジェニンの分解物は、プロテアーゼでアンジ
オジェニンを加水分解したものなどを用いることができ
る。アンジオジェニンの加水分解に用いることのできる
プロテアーゼとしては、トリプシン、キモトリプシン、
サーモリシン、ズブチリシン、パパイン、ペプシンなど
を例示することができ、これらのプロテアーゼを基質に
対して重量比1/30〜1/200の割合で用いると良
い。基質濃度については特に制限されないが、あまり粘
度の上昇しない10%以下程度が好ましい。酵素反応は
通常37℃で行うが、サーモリシンを用いる場合は40
℃で酵素反応を行うと良い。なお、これらのプロテアー
ゼ処理は、20〜42℃の範囲で行うことができる。ま
た、酵素反応に適したpH領域は、トリプシン、キモト
リプシン、サーモリシン及びズブチリシンを用いる場合
が7〜8、パパインを用いる場合が5〜8、ペプシンを
用いる場合が2〜3である。酵素反応を行う時間につい
ては、余り長時間であるとアンジオジェニンが極端に低
分子化してしまうので、10分間〜10時間、好ましく
は10分間〜4時間の範囲で行うと良い。As the decomposition product of angiogenin used as an active ingredient of the growth promoting agent in the present invention, those obtained by hydrolyzing angiogenin with a protease can be used. Proteases that can be used for the hydrolysis of angiogenin include trypsin, chymotrypsin,
Examples thereof include thermolysin, subtilisin, papain, pepsin, and the like, and these proteases are preferably used in a weight ratio of 1/30 to 1/200 with respect to the substrate. The substrate concentration is not particularly limited, but is preferably about 10% or less at which the viscosity does not increase so much. The enzyme reaction is usually carried out at 37 ° C, but when thermolysin is used, it is 40
It is better to carry out the enzyme reaction at ℃. In addition, these protease treatments can be performed in the range of 20 to 42 ° C. The pH range suitable for the enzymatic reaction is 7 to 8 when trypsin, chymotrypsin, thermolysin and subtilisin are used, 5 to 8 when papain is used, and 2 to 3 when pepsin is used. Regarding the time for carrying out the enzymatic reaction, if the time is too long, angiogenin will be extremely reduced in molecular weight, and therefore, it may be carried out within a range of 10 minutes to 10 hours, preferably 10 minutes to 4 hours.
【0007】本発明のアンジオジェニンおよび/または
その分解物を有効成分とする発育促進剤は、アンジオジ
ェニンおよび/またはその分解物を糖衣錠やタブレット
などの錠剤、顆粒剤、液剤、もしくはカプセルなどとし
て経口的に投与できる形体で用いることができる。ま
た、本発明のアンジオジェニンおよび/またはその分解
物を有効成分とする発育促進剤を各種飲食品、例えば飲
料、スープ、ゼリー、パン、麺、ソーセージなどに添加
して用いることもできる。さらに、本発明のアンジオジ
ェニンおよび/またはその分解物を有効成分とする発育
促進剤を配合した飼料は、ウシ、ウマ、ヤギ、ブタ、ヒ
ツジ、ウサギなどの家畜、イヌ、ネコなどのペット動
物、その他の飼育動物、実験動物などに投与することが
できる。The growth promoting agent of the present invention containing angiogenin and / or its degradation product as an active ingredient is orally administered as angiogenin and / or its degradation product as tablets such as sugar-coated tablets and tablets, granules, liquids or capsules. It can be used in a form that can be administered locally. Further, the growth promoting agent containing the angiogenin of the present invention and / or its decomposition product as an active ingredient may be added to various foods and drinks such as beverages, soups, jellies, breads, noodles, sausages and the like for use. Furthermore, the feed containing the growth promoting agent containing the angiogenin and / or its degradation product of the present invention as an active ingredient, cattle, horses, goats, pigs, sheep, domestic animals such as rabbits, pet animals such as dogs and cats, It can be administered to other domestic animals, experimental animals and the like.
【0008】本発明の発育促進剤を飲食品あるいは飼料
に添加するに際しては、膜によって除菌したアンジオジ
ェニンを添加することが望ましいが、温和な条件でアン
ジオジェニンを加熱殺菌することも可能である。飲食品
あるいは飼料にアンジオジェニンを添加した後、加熱殺
菌する場合は、アンジオジェニンの活性が2/3程度に
低下することを考慮しておく必要がある。When the growth promoter of the present invention is added to food or drink or feed, it is desirable to add angiogenin sterilized by a membrane, but it is also possible to heat sterilize the angiogenin under mild conditions. . When angiogenin is added to food or drink or feed and then heat-sterilized, it is necessary to consider that the activity of angiogenin is reduced to about 2/3.
【0009】本発明において、アンジオジェニンおよび
/またはその分解物の投与量については特に制限はない
が、1日の投与量は、体重1kg当たり、1〜100m
gを一応の目安とすると良い。すなわち、投与量が1m
g/kg以下であると発育促進効果が殆ど認められず、
また、投与量が100mg/kg以上では発育促進効果
の顕著な上昇は見られない。なお、アンジオジェニンは
乳中に多量に含まれる物質であり、その安全性について
は問題がないといえる。次に本発明の実施例を挙げて具
体的に説明する。In the present invention, the dose of angiogenin and / or its degradation product is not particularly limited, but the daily dose is 1 to 100 m / kg of body weight.
It is good to use g as a rough guide. That is, the dose is 1 m
When it is g / kg or less, almost no growth promoting effect is recognized,
Further, when the dose is 100 mg / kg or more, the growth-promoting effect is not significantly increased. Since angiogenin is a substance contained in milk in a large amount, it can be said that there is no problem in its safety. Next, an example of the present invention will be specifically described.
【0010】[0010]
【実施例1】スルホン化キトパール(富士紡績(株)
製)30Lを充填したカラム(直径1.5m×高さ18
cm)に生脱脂乳3,000kgを1,800kg/h
の流速で3回繰り返して通液した。通液後、カラムを3
0〜35℃の温湯100Lを通液して十分洗浄し、0.
7M塩化ナトリウムを含む0.5mM炭酸水素ナトリウ
ム(pH7.5)溶液50L通液して溶出液49kgを
回収した。次に、この溶出液を分画分子量50,000
の限外濾過膜を装着した限外濾過装置で濃縮、脱塩し、
凍結乾燥してアンジオジェニンを含む画分263gを得
た。[Example 1] Sulfonated chitopearl (Fuji Spinning Co., Ltd.)
Column made of 30 L (diameter 1.5 m x height 18)
cm), raw skim milk 3,000 kg, 1,800 kg / h
The liquid was repeatedly passed through at a flow rate of 3 times. After passing through the liquid, set the column to 3
100 L of hot water at 0 to 35 ° C is passed through to thoroughly wash, and
50 L of a 0.5 mM sodium hydrogen carbonate (pH 7.5) solution containing 7 M sodium chloride was passed through to collect 49 kg of an eluate. Next, this eluate was subjected to molecular weight cut-off of 50,000.
Concentrated and desalted with an ultrafiltration device equipped with the ultrafiltration membrane of
Lyophilization gave 263 g of a fraction containing angiogenin.
【0011】さらに、純度を高めるため、このアンジオ
ジェニン含有画分720mgを3Mチオシアン酸ナトリ
ウムを含む10mMトリス−塩酸緩衝液(pH7.0)
26Lに溶解して1,000rpmで30分間の遠心分
離を行って不溶解物を除去した。次に、この上清にエタ
ノール濃度が80%となるよう冷エタノールを加え、−
40℃で4時間放置した後、1,000rpmで30分
間の遠心分離を行って沈殿を除去した。そして、この上
清を分画分子量2,000の限外濾過膜を装着した限外
濾過装置で濃縮、脱塩し、凍結乾燥してアンジオジェニ
ン粉末10.3gを得た。Further, in order to improve the purity, 720 mg of the angiogenin-containing fraction was added to a 10 mM Tris-hydrochloric acid buffer solution (pH 7.0) containing 3M sodium thiocyanate.
It was dissolved in 26 L and centrifuged at 1,000 rpm for 30 minutes to remove insoluble matter. Next, cold ethanol was added to this supernatant so that the ethanol concentration was 80%,
After standing at 40 ° C. for 4 hours, centrifugation was performed at 1,000 rpm for 30 minutes to remove the precipitate. Then, the supernatant was concentrated, desalted by an ultrafiltration device equipped with an ultrafiltration membrane having a molecular weight cut off of 2,000, and freeze-dried to obtain 10.3 g of angiogenin powder.
【0012】[0012]
【実施例2】アンジオジェニン3gを60mlの10m
Mリン酸−リン酸ナトリウム緩衝液(pH7.0)に溶
解し、トリプシン(シグマ社製)60mgを添加して、
37℃、1時間の反応を行った後、90℃、10分間の
加熱処理を行って反応を停止させ、さらに、10,00
0×G、10分間の遠心分離を行って沈殿物を除去し
た。このようにして得られた反応生成物を凍結乾燥し、
アンジオジェニン分解物粉末2.6gを得た。Example 2 Angiogenin 3 g was added to 60 ml of 10 m.
It is dissolved in M phosphate-sodium phosphate buffer (pH 7.0), and 60 mg of trypsin (manufactured by Sigma) is added,
After the reaction was carried out at 37 ° C. for 1 hour, the reaction was stopped by performing a heat treatment at 90 ° C. for 10 minutes.
The precipitate was removed by centrifugation at 0 × G for 10 minutes. The reaction product thus obtained is freeze-dried,
2.6 g of angiogenin degradation product powder was obtained.
【0013】[0013]
【試験例】実施例1で調製したアンジオジェニン及び実
施例2で調製したアンジオジェニン分解物のラットに対
する発育促進効果を試験した。この試験には、生後16
日で離乳したウイスター系ラットを用い、1群4匹で、
A群はアンジオジェニンを投与しなかった群、B群はア
ンジオジェニンを0.1mg/日/kgの割合で1日1
回強制投与した群、C群はアンジオジェニンを1mg/
日/kgの割合で1日1回強制投与した群、D群はアン
ジオジェニンを50mg/日/kgの割合で1日1回強
制投与した群、E群はアンジオジェニンを200mg/
日/kgの割合で1日1回強制投与した群、F群はアン
ジオジェニン分解物を50mg/日/kgの割合で1日
1回強制投与した群とした。なお、この試験では、カゼ
イン20重量%、セルロース5重量%、コーンスターチ
15重量%、シュークロース45重量%、ビタミン類1
重量%、ミネラル類3.5重量%、重酒石酸コリン0.
2重量%、DL−メチオニン0.3重量%及び大豆油1
0重量%に調製した食餌を投与した。また、水は自由摂
取とした。試験開始時及び試験開始後10日のラットの
体重を表1に示す。[Test Example] The angiogenin prepared in Example 1 and the angiogenin degradation product prepared in Example 2 were tested for their growth promoting effect on rats. 16 years old for this test
Using Wistar rats weaned daily, 4 animals per group,
Group A did not receive angiogenin, and group B received angiogenin at a rate of 0.1 mg / day / kg, 1 a day.
1 group / mg of angiogenin in the group that was forcibly administered once
The group was forcibly administered once a day at a rate of 1 day / kg, the group D was forcibly administered angiogenin at a rate of 50 mg / day / kg once a day, and the group E was 200 mg for angiogenin /
The group was forcibly administered once a day at the rate of day / kg, and the group F was a group forcibly administered the angiogenin degradation product at the rate of 50 mg / day / kg once a day. In this test, casein 20% by weight, cellulose 5% by weight, corn starch 15% by weight, sucrose 45% by weight, vitamins 1
% By weight, 3.5% by weight of minerals, choline bitartrate 0.
2% by weight, DL-methionine 0.3% by weight and soybean oil 1
The diet adjusted to 0% by weight was administered. Also, water was freely available. Table 1 shows the body weights of the rats at the start of the test and 10 days after the start of the test.
【0014】[0014]
【表1】 ──────────────────────────────── 群 試験開始時(g) 試験開始後10日(g) ──────────────────────────────── A 36±2 80±2 B 35±2 81±3 C 36±2 88±3* D 36±2 94±4* E 37±2 93±4* F 36±3 91±5* ──────────────────────────────── 平均値±標準偏差で表示、*は危険率5%で有意差あり A群に対し、C、D、E群及びF群では、有意に体重の
増加が認められ、幼若動物の発育促進にアンジオジェニ
ン及びアンジオジェニン分解物が寄与することが示され
た。[Table 1] ──────────────────────────────── Group Start of test (g) 10 days after start of test (g ) ──────────────────────────────── A 36 ± 2 80 ± 2 B 35 ± 2 81 ± 3 C 36 ± 2 88 ± 3 * D 36 ± 2 94 ± 4 * E 37 ± 2 93 ± 4 * F 36 ± 3 91 ± 5 * ────────────────────── ─────────── Displayed as mean ± standard deviation, * indicates a significant difference with a risk rate of 5%. Significant increase in body weight in groups C, D, E and F compared to group A Was observed, and it was shown that angiogenin and angiogenin degradation products contribute to the growth promotion of juvenile animals.
【0015】[0015]
【実施例3】実施例1で調製したアンジオジェニン1
g、ショ糖3.2g、クエン酸53g、クエン酸ナトリ
ウム53g、ビタミンB2 0.06g、ビタミンC
0.37g、葉酸0.03g、香料6.7g、5倍濃縮
アップル果汁134g及び水3.5kgを混合した組成
物を63℃、30分間保持して加熱殺菌した後、5〜1
0℃に冷却して殺菌済容器中に貯蔵した。次いで、この
混合液を殺菌済の200ml容紙容器に無菌的に充填
し、乳幼児用の発育促進補助飲料を製造した。Example 3 Angiogenin 1 prepared in Example 1
g, sucrose 3.2 g, citric acid 53 g, sodium citrate 53 g, vitamin B 2 0.06 g, vitamin C
A composition obtained by mixing 0.37 g, folic acid 0.03 g, fragrance 6.7 g, 5-fold concentrated apple juice 134 g and water 3.5 kg was held at 63 ° C. for 30 minutes for heat sterilization, and then 5-1
It was cooled to 0 ° C. and stored in sterile containers. Next, this mixed solution was aseptically filled in a sterilized 200 ml paper container to produce a growth-promoting supplement beverage for infants.
【0016】[0016]
【実施例4】無脂乳固形11.5%で酵母エキス0.5
%を含む脱脂乳培地で、ビフィドバクテリウム・ロンガ
ム SBT 2933R(微工研菌寄第8743号) 、
ストレプトコッカス・サーモフィルス SBT 102
1A(微工研菌寄第10658号) 及びラクトバチルス
・アシドフィルス SBT 2062(微工研菌寄第1
0730号) を31℃の温度で培養した。培養終了後、
実施例1で調製したアンジオジェニン1.5gを添加
し、複合菌スターターとした。Example 4 Non-fat milk solids 11.5% and yeast extract 0.5
% Non-fat milk medium, Bifidobacterium longum SBT 2933R (Microtechnology Research Institute No. 8743),
Streptococcus thermophilus SBT 102
1A (Microtech Lab. No. 10658) and Lactobacillus acidophilus SBT 2062 (Microtech Lab. No. 1
No. 0730) was cultured at a temperature of 31 ° C. After culturing,
1.5 g of angiogenin prepared in Example 1 was added to give a complex bacterial starter.
【0017】一方、牛乳4.4Lに脱脂粉乳40gを加
えて攪拌、混合した後、温度60℃〜70℃、均質圧1
00〜270kg/cm2 で均質処理を行った原料ミッ
クスを90〜95℃で10〜15分間保持して加熱殺菌
した後、38℃に冷却した。この原料ミックスに上記の
複合菌スターター500mlを接種し、38℃で5時間
発酵させた後、10℃以下に冷却した。こうして得られ
た発酵乳5Lに、砂糖100g、キサンタンガム5g及
びオレンジフレーバー5gを混合溶解した糖液混合物1
Lを添加して攪拌した後、均質圧100〜270kg/
cm2 で均質処理を行い、乳幼児用の発育促進効果を付
与した乳酸菌飲料を製造した。On the other hand, 40 g of skim milk powder was added to 4.4 L of milk, stirred and mixed, and then the temperature was 60 ° C. to 70 ° C. and the homogenous pressure was 1
The raw material mix homogenized at 00 to 270 kg / cm 2 was held at 90 to 95 ° C for 10 to 15 minutes for heat sterilization, and then cooled to 38 ° C. This raw material mix was inoculated with 500 ml of the above-described complex bacterial starter, fermented at 38 ° C for 5 hours, and then cooled to 10 ° C or lower. Sugar liquid mixture 1 in which 100 g of sugar, 5 g of xanthan gum and 5 g of orange flavor were mixed and dissolved in 5 L of the fermented milk thus obtained
After adding L and stirring, a homogeneous pressure of 100 to 270 kg /
Homogeneous treatment was carried out at cm 2 , to produce a lactic acid bacterium beverage with a growth promoting effect for infants.
【0018】[0018]
【実施例5】脱脂乳1,195g、ホエー粉263g、
植物油119g、ビタミン・ミネラル類5g及び実施例
1で調製したアンジオジェニン2gを配合して、乳幼児
用の発育促進効果を付与した育児用粉乳1,584gを
製造した。Example 5 1,195 g of skim milk, 263 g of whey powder,
119 g of vegetable oil, 5 g of vitamins and minerals, and 2 g of angiogenin prepared in Example 1 were mixed to produce 1,584 g of infant formula milk powder having a growth-promoting effect.
【0019】[0019]
【実施例6】実施例1で調製したアンジオジェニン25
0mg、乳糖33.3mg、トウモロコシデンプン1
6.4mg、カルボキシメチルセルロースカルシウム1
2.8mg及びステアリン酸マグネシウム1.5mgを
配合し、常法に従って錠剤の発育促進剤を製造した。Example 6 Angiogenin 25 prepared in Example 1
0 mg, lactose 33.3 mg, corn starch 1
6.4 mg, carboxymethyl cellulose calcium 1
2.8 mg and 1.5 mg of magnesium stearate were blended to prepare a tablet growth promoter according to a conventional method.
【0020】[0020]
【実施例7】実施例1で調製したアンジオジェニン40
0mg、乳糖883mg、トウモロコシデンプン221
mg及びヒドロキシプロピルセルロース16mgを配合
し、常法に従って顆粒剤の発育促進剤を製造した。Example 7 Angiogenin 40 prepared in Example 1
0 mg, lactose 883 mg, corn starch 221
mg and hydroxypropyl cellulose 16 mg were blended to prepare a growth promoter for granules according to a conventional method.
【0021】[0021]
【実施例8】脱脂粉乳60g、WPC14.3g、脂肪
17.2g、グルコース5.0g、ビタミン・ミネラル
類2.5g及び実施例1で調製したアンジオジェニン1
0mgを配合して幼若動物用の配合飼料を製造した。Example 8 Skim milk powder 60 g, WPC 14.3 g, fat 17.2 g, glucose 5.0 g, vitamins and minerals 2.5 g and angiogenin 1 prepared in Example 1
0 mg was compounded to produce a compounded feed for young animals.
【0022】[0022]
【発明の効果】本発明のアンジオジェニンおよび/また
はその分解物を有効成分とする発育促進剤は、医薬とし
ては勿論、飲食品や飼料などに発育促進効果を付与する
ことのできる素材として利用することができる。また、
アンジオジェニンは、乳中に比較的多量に含まれている
ので、本発明の発育促進剤を安定的に提供することが可
能である。The growth promoting agent of the present invention containing angiogenin and / or its degradation product as an active ingredient is used not only as a medicine but also as a material capable of imparting a growth promoting effect to foods and drinks and feeds. be able to. Also,
Since angiogenin is contained in milk in a relatively large amount, it is possible to stably provide the growth promoting agent of the present invention.
Claims (1)
解物を有効成分とする発育促進剤。1. A growth promoter comprising angiogenin and / or its degradation product as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5057960A JPH06247871A (en) | 1993-02-23 | 1993-02-23 | Growth promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5057960A JPH06247871A (en) | 1993-02-23 | 1993-02-23 | Growth promoter |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06247871A true JPH06247871A (en) | 1994-09-06 |
Family
ID=13070589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5057960A Pending JPH06247871A (en) | 1993-02-23 | 1993-02-23 | Growth promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH06247871A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0869134A1 (en) * | 1997-03-27 | 1998-10-07 | Campina Melkunie B.V. | Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative |
JPWO2014020677A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
JPWO2014020680A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
JPWO2014020679A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
JPWO2014020678A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
JP2016152809A (en) * | 2016-04-05 | 2016-08-25 | 雪印メグミルク株式会社 | Beverage and manufacturing method therefor |
-
1993
- 1993-02-23 JP JP5057960A patent/JPH06247871A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0869134A1 (en) * | 1997-03-27 | 1998-10-07 | Campina Melkunie B.V. | Process for recovering growth factors, or a composition containing one or more growth factors, from milk or a milk derivative |
JPWO2014020677A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
JPWO2014020680A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
JPWO2014020679A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Fermented milk and method for producing the same |
JPWO2014020678A1 (en) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | Beverage and method for producing the same |
JP2016152809A (en) * | 2016-04-05 | 2016-08-25 | 雪印メグミルク株式会社 | Beverage and manufacturing method therefor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6234227B2 (en) | Nutritional composition for improving intestinal flora | |
EP1085816B1 (en) | Dietary supplement derived from fermented milks for the prevention of osteoporosis | |
US11241018B2 (en) | Process for preparing oligo-saccharide enhanced milk products | |
CN105705037A (en) | Nutritional composition for inhibiting growth of tumor | |
WO2005016373A1 (en) | Osteogenesis promoter | |
US4756913A (en) | Sour milk product | |
TWI620506B (en) | Use of yoghurt and method of manufacturing same | |
JP2009044976A (en) | Animal body type-improving feeding system | |
KR20200011584A (en) | Novel protein material | |
JPH06247871A (en) | Growth promoter | |
JP2004238320A (en) | Bone absorption inhibitor | |
CN114794235B (en) | Chickpea polypeptide yoghurt and preparation method thereof | |
JP4688457B2 (en) | Immune enhancing composition | |
RU2268599C2 (en) | Composition for manufacturing of fermented milky beverage and method for production thereof | |
JP3505043B2 (en) | Vitamin K supplements and foods for osteoporosis prevention and treatment | |
JP2004154086A (en) | Malted rice/soymilk-containing yoghurt food and method for producing the same | |
JP2001226289A (en) | Hepatic function ameliorative agent | |
Sydney et al. | Colostrum new insights: products and processes | |
JP7474596B2 (en) | Novel Bifidobacterium bacteria, compositions containing said bacteria, and compositions for promoting the growth of said bacteria | |
JP3587536B2 (en) | Calcium reinforcing agent and method for producing the same | |
JP3789146B2 (en) | Oligosaccharide-containing nutritional composition | |
WO2013133326A1 (en) | Bone-strengthening agent | |
Hazra et al. | Nutritive value and health benefit of fermented milks | |
TWI804459B (en) | Use of lactoperoxidase, cystatin, hmg protein and/or degradation products thereof | |
JP2008150340A (en) | Growth hormone secretagogue |